Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 14/20 | 1.00 |
| ▸ | XIAP | P98170 | 4/20 | 0.47 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121979 | 1.00 | PARG (1.00) | PARGXIAPBIRC2HDAC3HDAC4 | |
| SCHEMBL17845347 | 0.85 | PARG (1.00) | PARGXIAPBIRC2HDAC3HDAC4 | |
| SCHEMBL17845439 | 0.84 | PARG (1.00) | PARGXIAPBIRC2HDAC3HDAC4 | |
| SCHEMBL28524806 | 0.83 | PARG (0.71) | PARGXIAPBIRC2HDAC3HDAC4 | |
| SCHEMBL17845461 | 0.79 | PARG (0.65) | PARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL31121991 | 0.79 | PARG (0.65) | PARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL31122083 | 0.67 | PARG (0.51) | PARG | |
| SCHEMBL28543059 | 0.66 | PARG (0.69) | PARGXIAPBIRC2 | |
| SCHEMBL23652919 | 0.65 | PARG (0.67) | PARGXIAPBIRC2 | |
| SCHEMBL23613807 | 0.65 | PARG (0.46) | PARGXIAPBIRC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | claimed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | claimed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | claimed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | claimed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | claimed |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | PARP11, PARG, PARP16 | PARG 2/4885XIAP 550/4885BIRC2 2216/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PARG 1/4885XIAP 488/4885BIRC2 2237/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | PARG 2/4885XIAP 550/4885BIRC2 2216/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PARG 1/4885XIAP 488/4885BIRC2 2237/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PARG 1/4885XIAP 488/4885BIRC2 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.